Eyepoint Pharmaceuticals (EYPT) Competitors $9.71 -0.11 (-1.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.76 +0.05 (+0.57%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYPT vs. TXG, TRNS, ALNT, LAB, AEHR, CTKB, SENS, QSI, QTRX, and MASSShould you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Allient (ALNT), Standard BioTools (LAB), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Quanterix (QTRX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Eyepoint Pharmaceuticals vs. Its Competitors 10x Genomics Transcat Allient Standard BioTools Aehr Test Systems Cytek Biosciences Senseonics Quantum-Si Quanterix 908 Devices 10x Genomics (NASDAQ:TXG) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do insiders & institutionals believe in TXG or EYPT? 84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 9.4% of 10x Genomics shares are owned by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer TXG or EYPT? In the previous week, 10x Genomics had 3 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 10 mentions for 10x Genomics and 7 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.72 beat Eyepoint Pharmaceuticals' score of 0.43 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TXG or EYPT? 10x Genomics currently has a consensus target price of $13.23, indicating a potential upside of 1.13%. Eyepoint Pharmaceuticals has a consensus target price of $25.67, indicating a potential upside of 164.33%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42Eyepoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, TXG or EYPT? 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Is TXG or EYPT more profitable? 10x Genomics has a net margin of -25.14% compared to Eyepoint Pharmaceuticals' net margin of -261.91%. 10x Genomics' return on equity of -23.22% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Eyepoint Pharmaceuticals -261.91%-54.27%-41.75% Which has higher earnings and valuation, TXG or EYPT? Eyepoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.64-$182.63M-$1.30-10.06Eyepoint Pharmaceuticals$56.04M11.92-$130.87M-$2.41-4.03 Summary10x Genomics beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Eyepoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYPT vs. The Competition Export to ExcelMetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$675.72M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-4.0317.6228.6723.80Price / Sales11.92179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book1.978.508.275.55Net Income-$130.87M-$55.06M$3.24B$259.03M7 Day Performance-7.35%-3.98%-3.69%-4.59%1 Month Performance0.52%9.59%4.33%4.46%1 Year Performance10.97%6.72%25.95%18.03% Eyepoint Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYPTEyepoint Pharmaceuticals1.91 of 5 stars$9.71-1.1%$25.67+164.3%+6.4%$675.72M$56.04M-4.03120News CoverageUpcoming EarningsTXG10x Genomics3.6626 of 5 stars$11.54-5.0%$14.13+22.4%-33.5%$1.50B$610.78M-8.881,240News CoverageUpcoming EarningsAnalyst ForecastShort Interest ↑Gap DownTRNSTranscat3.3348 of 5 stars$80.43-1.1%$112.20+39.5%-32.9%$757.43M$278.42M51.561,245Upcoming EarningsALNTAllient2.3313 of 5 stars$38.57-3.1%$31.00-19.6%+38.5%$674.11M$529.97M65.372,525News CoveragePositive NewsUpcoming EarningsLABStandard BioTools3.3855 of 5 stars$1.26+2.4%$2.50+98.4%-8.5%$467.18M$174.43M-3.60620News CoveragePositive NewsGap DownAEHRAehr Test Systems1.6485 of 5 stars$16.45+9.2%N/A+1.8%$448.65M$58.97M-126.5390CTKBCytek Biosciences2.3493 of 5 stars$3.10-1.0%$5.60+80.6%-43.2%$396.44M$200.45M-34.44500Positive NewsUpcoming EarningsSENSSenseonics1.6275 of 5 stars$0.58-0.4%$1.55+168.3%+21.1%$378.01M$23.68M-4.4490QSIQuantum-Si2.5306 of 5 stars$1.72-2.3%$3.48+102.0%+47.6%$322.96M$3.06M-2.53150Upcoming EarningsGap DownQTRXQuanterix2.2425 of 5 stars$5.18-3.5%$13.50+160.6%-58.3%$268.25M$137.42M-3.98460Positive NewsUpcoming EarningsMASS908 Devices2.115 of 5 stars$6.96+3.9%$5.33-23.4%+26.4%$240.27M$59.63M-12.8960Positive NewsUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies TXG Alternatives TRNS Alternatives ALNT Alternatives LAB Alternatives AEHR Alternatives CTKB Alternatives SENS Alternatives QSI Alternatives QTRX Alternatives MASS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYPT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
